TestRAMP to Launch Genomic Testing Marketplace
Published By Pressat [English], Fri, Mar 25, 2022 5:58 AM
TestRAMP is launching a ‘one stop shop’ to help healthcare providers source genomic testing from commercial labs.
The not-for-profit company, which runs a marketplace for lab-based Covid-19 PCR testing, will be providing the same service for other diseases, such as cancer and Alzheimer’s.
Mike Hudson, CEO, said “We want to put our experience of working with the UK’s top genomic laboratories to good use post-pandemic. Covid testing grew the capacity and expertise of PCR and genomic sequencing labs – now they are well placed to offer molecular testing for other serious diseases.”
The company believe that by creating a genomic testing marketplace it can help to harness the capacity of these labs for non-Covid testing, to give faster, wider, cheaper access to genomic testing both in traditional healthcare settings, and using ‘at home’ tests.
Mr Hudson said “We’re creating a marketplace so that healthcare providers can see which labs offer particular genomic tests, how much they cost and how quickly they are deliverable”
“We’ll also be helping labs to co-operate with each other, including to manage supply and demand”
During the pandemic, TestRAMP generated £2.4 million for charities including Alzheimer’s Society, ZSL and Pilgrims Hospices. Mr Hudson said this work would continue both through TestRAMP and through their recently formed charitable foundation, TestAID.
“We say that we are 100% commercial and 100% philanthropic. That means we charge clients fees, but we operate as a not-for-profit and donate most of our revenue to charity. Our objective is to make diagnostic testing work better and to support charities at the same time”.
“Hopefully the worst of the pandemic is behind us in the UK, and the need for Covid PCR testing is much reduced, although we do of course continue to support Covid labs where needed”.
For more information please contact mikehudson@testramp.org
Press release distributed by Media Pigeon on behalf of Pressat, on Mar 25, 2022. For more information subscribe and follow